TAIKO PHARMACEUTICAL CO.,LTD. Environmental Analytics
Environmental and financial analysis dashboard for TAIKO PHARMACEUTICAL CO.,LTD.. Industry: MANUFACTURING
Company Overview for TAIKO PHARMACEUTICAL CO.,LTD.
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.80m
Operational Environmental Cost Intensity
2.09%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$-4.31m
Decoupling Rate (2020-2022)
17%
Adjusted EBITDA
$-32m
Adjusted EBITDA Margin
-84%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -46.17% | -75.71% | -7.80% | ||
| 1.65% | 1.54% | 0.96% | 0.78% | |
| -46.35% | -65.03% | 26.33% | ||
| 1.35% | 1.26% | 1.13% | 1.26% | |
| $5m | $3m | $1m | $1m | |
| -46.25% | -70.91% | 10.66% | ||
| 3.00% | 2.80% | 2.09% | 2.04% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-84%
Adjusted EBIT Margin
-98%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$170m | $98m | $38m | $43m | |
| -42.38% | -61.07% | 13.59% | ||
$114m | $171m | $69m | $64m | |
| 66.93% | 174.07% | 181.79% | 146.58% | |
$56m | $-73m | $-31m | $-20m | |
| 33.07% | -74.07% | -81.79% | -46.58% | |
$52m | $-81m | $-37m | $-25m | |
| 30.39% | -82.85% | -96.41% | -58.09% | |
| ENVIRONMENTAL COST DATA | ||||
$5m | $3m | $1m | $1m | |
| 3.00% | 2.80% | 2.09% | 2.04% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$51m | $-75m | $-32m | $-21m | |
| 30.07% | -76.86% | -83.88% | -48.62% | |
$47m | $-84m | $-38m | $-26m | |
| 27.39% | -85.64% | -98.50% | -60.12% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.96%
Scope 2 (% of Sales)
1.13%
Operational Environmental Cost Intensity
2.09%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
TAIKO PHARMACEUTICAL CO.,LTD. | N/A | $1m | 2.09% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022